A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

 

 Buy Article Permissions and Reprints

Abstract

Aims: The aim of the trial was to compare the efficacy and safety of the new, long-acting basal insulin, insulin glargine (LANTUS®), with NPH human insulin, each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes. Methods: In a multicentre, open, randomised study, 570 patients with Type 2 diabetes, aged 34 - 80 years, were treated for 52 weeks with insulin glargine or NPH insulin given once daily at bedtime. Previous oral antidiabetic therapy was continued throughout the study. Results: There was a clinically relevant decrease in glycosylated haemoglobin (GHb) values from baseline to endpoint with both drugs (insulin glargine: - 0.46 %; NPH insulin: - 0.38 %; p = 0.415); also, this difference was statistically significant in the subgroup of overweight patients with BMI > 28 kg/m² (insulin glargine: - 0.42 %, NPH insulin: - 0.11 %; p = 0.0237). Over the entire treatment period, NPH insulin-treated patients (41 %) and insulin glargine-treated patients (35 %) experienced a similar level of symptomatic hypoglycaemia. A statistically significant difference was observed in the number of patients treated with NPH insulin who reported at least one episode of nocturnal hypoglycaemia compared with those treated with insulin glargine in the overall population and in the overweight subgroup (overall: 24 % vs. 12 %, p = 0.002; overweight: 22.2 % vs. 9.5 %, p = 0.0006), using the Cochran-Mantel-Haenszel test. These differences were most pronounced in insulin-naïve and overweight (BMI > 28 kg/m²) sub-groups. The incidence of adverse events was similar for the two treatments. Conclusions: This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes, and is associated with fewer episodes of symptomatic hypoglycaemia, particularly nocturnal episodes.

References

• 1 Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects.  Endocr Rev. 1998;  19 477-490
  CrossrefPubMedGoogle Scholar
• 2 Gerich J E. Addressing the insulin secretion defect: a logical first-line approach.  Metabolism. 2000;  49 12-16
  PubMedGoogle Scholar
• 3 UK Prospective Diabetes Study Group . Effect of intensive blood glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
  CrossrefPubMedGoogle Scholar
• 4 Riddle M. Timely addition of insulin to oral therapy for Type 2 diabetes.  Diabetes Care. 2002;  25 395-396
  PubMedGoogle Scholar
• 5 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  The Lancet. 1998;  352 837-853
  CrossrefPubMedGoogle Scholar
• 6 Genuth S. Insulin use in NIDDM.  Diabetes Care. 1990;  13 1240-1264
  PubMedGoogle Scholar
• 7 Greco A. et al . The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy.  Hormone and Metabolic Research. 1992;  24 280-283
  PubMedGoogle Scholar
• 8 Frier B. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes.  Int J Clin Pract Suppl. 2002;  129 12-19
  PubMedGoogle Scholar
• 9 Lepore M. et al . Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutanwous infusion of insulin lispro.  Diabetes. 2000;  49 2142-2148
  CrossrefPubMedGoogle Scholar
• 10 Rosskamp R H, Park G. Long-acting insulin analogs.  Diabetes Care. 1999;  22 B109-B113
  PubMedGoogle Scholar
• 11 Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes.  Diabetes Care. 2000;  23 1130-1136
  CrossrefPubMedGoogle Scholar
• 12 Rosenstock J. et al . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.  Diabetes Care. 2001;  24 631-636
  CrossrefPubMedGoogle Scholar
• 13 DCCT . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  New England Journal of Medicine. 1993;  329 977-986
  CrossrefPubMedGoogle Scholar

Prof. M. Massi Benedetti

Department of Medicina Interna · Università di Perugia

Via E. dal Pozzo · 06100 Perugia · Italy

Phone: + 39 (75) 57 27 627

Fax: + 39 (75) 57 27 627

Email: massi@unipg.it